Lexaria Extends Pharma Partner MTA Through December 31, 2026 as 2026 GLP-1 Data Cycle Approaches [TheStreet.com]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: TheStreet.com
It keeps Lexaria's DehydraTECH platform inside an active pharmaceutical evaluation as three GLP-1 readouts approach in the second half of the year. An eight-month extension on an active pharma evaluation Lexaria Bioscience Corp. ( Nasdaq: LEXX ) confirmed today that an undisclosed pharmaceutical partner extended its Material Transfer Agreement through December 31, 2026 . The original MTA, signed in August 2024, places Lexaria's DehydraTECH oral drug delivery technology inside a pre-clinical evaluation tied to the partner's proprietary asset. The extension keeps the temporary exclusive license in force. It also continues to limit DehydraTECH formulations specific to the partner's API to that single relationship. Beyond the license itself, the extended window opens the door to additional discussions with the partner's human clinical and business development teams. That is the natural next step in any technology evaluation that progresses beyond pharmacokinetic work. The window n
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is ExtendedACCESS Newswire
- Lexaria Bioscience (LEXX) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (e+)" to "sell (d-)".MarketBeat
- Lexaria Launches New Study to Examine Next-Generation GLP-1 DrugsACCESS Newswire
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales [Yahoo! Finance]Yahoo! Finance
- Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
LEXX
Sec Filings
- 4/13/26 - Form 10-Q
- 3/18/26 - Form 4
- 2/6/26 - Form 8-K
- LEXX's page on the SEC website